Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ В ПОЖИЛОМ И СТАРЧЕСКОМ ВОЗРАСТЕ: СОГЛАСОВАННОЕ МНЕНИЕ ЭКСПЕРТОВ

https://doi.org/10.15829/1728-8800-2017-3-4-33

Полный текст:

Аннотация

Рабочая группа:

Председатель: д.м.н., профессор Ткачева О. Н.

Заместитель председателя: д.м.н. Рунихина  Н. К.

Члены рабочей группы: д.м.н. Воробьева  Н. М., д.м.н. Комаров  А. Л., д.м.н., профессор Котовская Ю. В., д.м.н., профессор Панченко Е. П., к.м.н. Плохова Е. В., д.м.н., профессор Фролова  Е. В., д.м.н. Явелов И. С.

Комитет экспертов: профессор Аверков О. В. (Москва),  профессор Архипов М. В. (Екатеринбург), профессор Баранова Е. И. (Санкт-Петербург), член-корр. РАН Барбараш О. Л. (Кемерово), член- корр. РАН Бойцов С. А. (Москва),  профессор Болотнова Т. В. (Тюмень), профессор Галявич А. С. (Казань), д.м.н. Гиляров М. Ю. (Москва),  профессор Глезер М. Г. (Москва),  профессор Гринштейн Ю. И. (Красноярск), д.м.н. Дупляков  Д. В. (Самара), профессор Захарова Н. О. (Самара), д.м.н. Ильницкий  А. Н. (Москва),  профессор Караева  Е. В. (Тверь), академик  РАН Кириенко  А. И. (Москва), профессор Кобалава Ж. Д. (Москва),  профессор Козиолова Н. А. (Пермь),  профессор Конради  А. О. (Санкт-Петербург), д.м.н. Линчак Р. М. (Москва),  профессор Новикова Н. А. (Москва),  академик РАН Оганов Р. Г. (Москва),  профессор Павлова  Т. В. (Самара), профессор Прощаев К. И. (Москва), профессор Руда М. Я. (Москва),  профессор Терещенко С. Н. (Москва),  профессор Фомин И. В. (Нижний Новгород), профессор Чесникова А. И. (Ростов-на-Дону), профессор Якушин С. С. (Рязань).

Об авторах

О. Н. Ткачева
ФГБОУ ВО “Российский национальный исследовательский медицинский университет им. Н. И. Пирогова” Министерства здравоохранения Российской Федерации — Обособленное структурное подразделение “Российский геронтологический научно-клинический центр”; Российская ассоциация геронтологов и гериатров
Россия

Доктор медицинских наук, профессор,  директор РГНКЦ, ОСП ФГБОУ  ВО “РНИМУ  им. Н. И. Пирогова” МЗ РФ.

Москва



Н. К. Рунихина
ФГБОУ ВО “Российский национальный исследовательский медицинский университет им. Н. И. Пирогова” Министерства здравоохранения Российской Федерации — Обособленное структурное подразделение “Российский геронтологический научно-клинический центр”; Российская ассоциация геронтологов и гериатров
Россия

Доктор медицинских наук, заместитель  директора.

Москва



Н. М. Воробьёва
ФГБОУ ВО “Российский национальный исследовательский медицинский университет им. Н. И. Пирогова” Министерства здравоохранения Российской Федерации — Обособленное структурное подразделение “Российский геронтологический научно-клинический центр”; Российская ассоциация геронтологов и гериатров
Россия
Доктор медицинских наук, старший научный сотрудник лаборатории сердечно-сосудистого старения.

Москва



А. Л. Комаров
ФГБУ " Российский Кардиологический Научно-производственный Комплекс» МЗ РФ; Российская ассоциация геронтологов и гериатров
Россия
Доктор медицинских наук, ведущий научный сотрудник лаборатории клинических проблем атеротромбоза.

Москва



Ю. В. Котовская
ФГБОУ ВО “Российский национальный исследовательский медицинский университет им. Н. И. Пирогова” Министерства здравоохранения Российской Федерации — Обособленное структурное подразделение “Российский геронтологический научно-клинический центр”; Российская ассоциация геронтологов и гериатров
Россия

Доктор медицинских наук, профессор, руководитель лаборатории сердечно-сосудистого старения.

Москва



Е. П. Панченко
ФГБУ " Российский Кардиологический Научно-производственный Комплекс» МЗ РФ; Российская ассоциация геронтологов и гериатров
Россия

Доктор медицинских наук, профессор, руководитель лаборатории клинических проблем атеротромбоза.

Москва



Е. В. Плохова
ФГБОУ ВО “Российский национальный исследовательский медицинский университет им. Н. И. Пирогова” Министерства здравоохранения Российской Федерации — Обособленное структурное подразделение “Российский геронтологический научно-клинический центр”; Российская ассоциация геронтологов и гериатров
Россия

Кандидат медицинских наук,  научный сотрудник лаборатории сердечно-сосудистого старения.

Москва



Е. В. Фролова
ФГБОУ ВО “СЗГМУ им. и. и. Мечникова” МЗ РФ; Российская ассоциация геронтологов и гериатров
Россия

Доктор медицинских наук, профессор,  профессор  кафедры семейной медицины.

Москва



И. С. Явелов
ФГБУ "Государственный научно-исследовательский центр профилактической медицины" Минздрава России; Российская ассоциация геронтологов и гериатров
Россия

Доктор медицинских наук, Ведущий научный сотрудник отдела клинической кардиологии и молекулярной генетики.

Москва



Список литературы

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013; 34: 3028-34.

2. Andreotti F, Rocca B, Husted S, et al., on behalf of the ESC Thrombosis Working Group. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J 2015; 36: 3238-49.

3. Aronow WS. Approach to symptomatic coronary disease in the elderly: TIME to change? Lancet 2001; 358: 945-6.

4. Mari D, Ogliari G, Castaldi D, et al. Hemostasis and ageing. Immun Ageing 2008; 5: 12.

5. Dolan G, Neal K, Cooper P, et al. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994; 86: 798-803.

6. Gleerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. Angiology 1995; 46: 715-8.

7. Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost 2002; 28: 555-68.

8. Sakkinen PA, Cushman M, Psaty BM, et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 1998; 80: 134-9.

9. Ariens RA, Coppola R, Potenza I, Mannucci PM. The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. Blood Coagul Fibrinolysis 1995; 6: 433-7.

10. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a ‘set up’ for vascular disease. Circulation 2003; 107: 139-46.

11. Nedic O, Rattan SI, Grune T, Trougakos IP. Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology. Free Radic Res 2013; 47 (Suppl. 1): 28-38.

12. Laurent S. Defining vascular aging and cardiovascular risk. J Hypertens 2012; 30 (suppl.): S3-8.

13. Liochev SI. Reactive oxygen species and the free radical theory of aging. Free Radic Biol Med 2013; 60: 1-4.

14. Simmonds MJ, Meiselman HJ, Baskurt OK. Blood rheology and aging. J Geriatr Cardiol 2013; 10: 291-301.

15. Schmucker DL. Age-related changes in liver structure and function: implications for disease? Exp Gerontol 2005; 40: 650-9.

16. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex onthe clearance of cytochrome P450 3A substrates. Clin Pharmacokinet 2005; 44: 33-60.

17. Aymanns C, Keller F, Maus S, et al. Review on pharmacokinetics and pharmacodynamics and the aging kidney. Clin J Am Soc Nephrol 2010; 5: 314-27.

18. Beaufrere B, Morio B. Fat and protein redistribution with aging: metabolic considerations. Eur J Clin Nutr 2000; 54 (Suppl. 3): S48-53.

19. Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet 2000; 38: 271-90.

20. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84.

21. Zamora E, Lupon J, Vila J, et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study-4, chronic kidney disease epidemiology collaboration, and Cockroft-Gault formulas. JACC 2012; 59: 1709-15.

22. Karsch-Volk M, Schmid E, Wagenpfeil S, et al. Kidney function and clinical recommendations of drug dose adjustment in geriatric patients. BMC Geriatr 2013; 13: 92.

23. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.

24. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-307.

25. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J 2016; 37: 2893-962.

26. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and Secondary Prevention of Cardiovascular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e637S-68S.

27. Diagnostics and treatment of arterial hypertension. Clinical guidelines. Moscow, 2013: http://cardioweb.ru/klinicheskie-rekomendatsii. Russian (диагностика и лечение артериальной гипертонии. Клинические рекомендации. Москва, 2013: http://cardioweb.ru/klinicheskie-rekomendatsii).

28. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Eur Heart J 2013; 34: 2159-219.

29. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Eur Heart J 2016; 37: 2315-81.

30. Hernandez-Diaz S, Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk for upper gastrointestinal complications. BMC Med 2006; 4: 22.

31. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995; 311: 222-6.

32. Reid CM, Storey E, Wong TY, et al. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC Neurol 2012; 12: 3.

33. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 2014; 312: 2510-20.

34. Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008; 189: 105-9.

35. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.

36. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-83.

37. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382: 769-79.

38. Chen DK, Kim JS, Sutton DM. Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature. Arch Intern Med 1999; 159: 311-4.

39. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.

40. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.

41. CAPRIE SC. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.

42. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-21.

43. Sabatine MS, Morrow DA, Montalescot G, et al. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial. Circulation 2005; 112: 3846-54.

44. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-32.

45. Naverese EP, Andreotti F, Sculze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015; 350: h1628.

46. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-66.

47. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15.

48. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012; 367: 1297-309.

49. Roe MT, Goodman SG, Ohman EM, et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 2013; 128: 823-33.

50. Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013; 369: 999-1010.

51. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-619.

52. Riesmeyer JS, Salazar DE, Weerakkody GJ, et al. Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol 2012; 52: 789-97.

53. Hamm CW, Bassand J-P, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054.

54. Husted S, James S, Becker RC, et al. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet Inhibition and Patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5: 680-8.

55. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010; 122: 1056-67.

56. Montalescot G, van’t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-27.

57. James SK, Storey RF, Khurmi NS, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 2012; 125: 2914-21.

58. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98.

59. Hernandez AV, Westerhout CM, Steyerberg EW, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. Heart 2007; 93: 450-5.

60. Ndrepepa G, Kastrati A, Mehilli J, et al. Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation 2006; 114: 2040-6.

61. Mak KH, Effron MB, Moliterno DJ. Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Drugs Aging 2000; 16: 179-87.

62. Guagliumi G, Stone GW, Cox DA, et al. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2004; 110: 1598-604.

63. Hermanides RS, van Houwelingen G, Ottervanger JP, et al. On-TIME 2 trial investigators. The impact of age on effects of pre-hospital initiation of high bolus dose of tirofiban before primary angioplasty for ST-elevation myocardial infarction. Cardiovasc Drugs Ther 2011; 25: 323-30.

64. De Luca G, van’t Hof AW, Huber K, et al. Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevationmyocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors. Heart Vessels 2013; 29: 15-20.

65. Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin ReInfarction Study. Part II. Secondary coronary prevention with persantin and aspirin. JACC 1986; 7: 251-69.

66. Chesebro JH, Fuster V, Elveback LR, et al. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984; 310: 209-14.

67. Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 65: 422-6.

68. De Caterina R, Husted S, Wallentin L, et al. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 769-86.

69. Cohen M, Antman EM, Gurfinkel EP, Radley D. Enoxaparin in unstable angina non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. J Thromb Thrombolysis 2001; 12: 199-206.

70. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011; 378: 693-703.

71. Montalescot G, White HD, Gallo R et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-17.

72. Lopes RD, Alexander KP, Marcucci G, et al. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. Eur Heart J 2008; 29: 1827-33.

73. Armstrong PW, Chang WC, Wallentin L, et al. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. CMAJ 2006; 174: 1421-6.

74. Thomas D, Giugliano RP. ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. J Thromb Thrombolysis 2009; 27: 1-10.

75. Schiele F. Fondaparinux and acute coronary syndromes: update on the OASIS 5–6 studies. Vasc Health Risk Manag 2010; 6: 179-87.

76. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-76.

77. Budaj A, Eikelboom JW, Mehta SR, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009; 30: 655-61.

78. Roffi M, Patrono C, Collet J-P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315.

79. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 1519-30.

80. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-96.

81. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-30.

82. Steg PG, van ‘t Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013; 369: 2207-17.

83. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014; 384: 1849-58.

84. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.

85. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-16.

86. Lopes RD, Alexander KP, Manoukian SV, et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC 2009; 53: 1021-30.

87. Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011; 365: 1980-9.

88. Nairooz R, Sardar P, Amin H, et al. Meta-Analysis of Randomized Clinical Trials Comparing Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention and in Patients With ST-Segment Elevation Myocardial Infarction. Am J Cardiol 2014; 114: 250-9.

89. Navarese EP, Schulze V, Andreotti F, et al. Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome. JACC Cardiovasc Interv 2015; 8 (1 Pt B): 201-13.

90. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly. A systematic review. Drugs Aging 1999; 14: 303-12.

91. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.

92. Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing patterns inbclinical practice: implications for safer anticoagulation in the elderly population. Chest 2005; 127: 2049-56.

93. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-96.

94. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.

95. Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate — a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.

96. Eriksson B, Dahl O, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.

97. Eriksson B, Dahl O, Rosencher N, et al. Oral dabigatran etexilate versus subcutaneous enoxaparin for prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.

98. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015; 386: 154-62.

99. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.

100. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-72.

101. Lip GYH, Clemens A, Noack H, et al. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost 2014; 111: 933-42.

102. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation, published online October 30, 2014, DOI: 10.1161/CIRCULATIONAHA.114.012061.

103. Graham DJ, Reichman ME, Wernecke M, et al. Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation. JAMA Intern Med 2016; 176: 1662-71.

104. Hernandez I, Zhang Y. Comparing Stroke and Bleeding with Rivaroxaban and Dabigatran in Atrial Fibrillation: Analysis of the US Medicare Part D Data. Am J Cardiovasc Drugs 2016 Sep 14. doi 10.1007/s40256-016-0189-9.

105. Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non- vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017; 356: j510.

106. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014; 129: 961-70.

107. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.

108. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-72.

109. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010; 64: 956-67.

110. Turpie AG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty: pooled analysis of four studies. Thromb Haemost 2011; 105: 444-53.

111. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011; 365: 883-91.

112. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387-94.

113. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.

114. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.

115. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blinded, phase II trial. Lancet 2009; 374: 29-38.

116. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366: 9-19.

117. Advisory council: Ruda MYa, Syrkin AL, Panchenko EP, et al. The summary of the council of experts devoted to discussion of value of rivaroxaban in treatment of the patients with acute coronary syndrome. Atherothrombosis 2015; 2: 86-94. Russian (Экспертный совет: Руда М. Я., Сыркин А. Л, Панченко Е. П. и др. Резюме сове- та экспертов, посвященного обсуждению значения препарата ривароксабан в лечении больных, переживших острый коронарный синдром. Атеротромбоз 2015; 2: 86-94).

118. Raskob GE, Gallus AS, Pineo GF, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br 2012; 94: 257-64.

119. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Eng J Med 2011; 365: 981-92.

120. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35: 1864-72.

121. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-30.

122. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. New Engl J Med 2011; 364: 806-17.

123. Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med 2013; 369: 799-808.

124. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.

125. Verheugt FW. The early risk of thrombolytic therapy for acute myocardial infarction: incidence, mechanisms and possible prevention. J Cardiovasc Risk 1998; 5: 103-8.

126. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20.

127. de Boer MJ, Ottervanger JP, van ‘t Hof AW, et al. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. JACC 2002; 39: 1723-8.

128. Bueno H, Betriu A, Heras M, et al. Primary angioplasty vs. fibrinolysis in very old patients with acute myocardial infarction: TRIANA (TRatamiento del Infarto Agudo de miocardio eN Ancianos) randomized trial and pooled analysis with previous studies. Eur Heart J 2011; 32: 51-60.

129. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013; 368: 1379-87.

130. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.

131. White HD, Braunwald E, Murphy SA, et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur Heart J 2007; 28: 1066-71.

132. Thomas D, Giugliano RP. ExTRACT-TIMI 25 in perspective: key lessons regarding enoxaparin as an adjunct to fibrinolytic therapy. J Thromb Thrombolysis 2009; 27: 1-10.

133. Russian clinical guidelines about diagnostics, treatment and prophylaxis of venous thromboembolic complications. Phlebology 2010; 4 (1): 4-37. Russian (Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология 2010; 4 (1): 4-37).

134. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370: 1402-11.

135. The Russian clinical guidelines about performing thrombolytic therapy in patients with ischemic stroke. Moscow 2015: mosgorzdrav.ru/ru-RU/science/default/download/86.html. Russian (Российские клинические рекомендации по прове- дению тромболитической терапии при ишемическом инсульте. Москва 2015: mosgorzdrav.ru/ru-RU/science/default/download/86.html).

136. Chen Y, Li CH, Wang YX et al. Safety and Effectiveness of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in 80 Years and Older Acute Ischemic Stroke Patients. Cell Biochem Biophys 2015; 72: 883-8.

137. Pego PM, Nunes AP, Ferreira P, et al. Thrombolysis in Patients Aged over 80 Years Is Equally Effective and Safe. J Stroke Cerebrovasc Dis 2016; 25: 1532-8.

138. Sagnier S, Galli P, Poli M, et al. The impact of intravenous thrombolysis on outcome of patients with acute ischemic stroke after 90 years old. BMC Geriatr 2016; 16: 156.

139. Arora R, Salamon E, Katz JM, et al. Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age. Stroke 2016; 47: 2347-54.

140. Fried LP, Ferrucci L, Darer J, et al. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59: 255-63.

141. Bales CW, Ritchie CS. Sarcopenia, weight loss, and nutritional frailty in the elderly. Annu Rev Nutr 2002; 22: 309-23.

142. Hubbard RE, Andrew MK, Rockwood K. Effect of parental age at birth on the accumulation of deficits, frailty and survival in older adults. Age Ageing 2009; 38: 380-5.

143. Walston J, McBurnie MA, Newman A, et al.; Cardiovascular Health Study. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 2333-41.

144. Bajorek BV, Krass I, Ogle SJ, et al. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc 2005; 53: 1912-20.

145. Man-Son-Hing M, Laupacis A. Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians’ fears often unfounded. Arch Intern Med 2003; 163: 1580-6.

146. Perera V, Bajorek BV, Matthews S, et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009; 38: 156-62.

147. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999; 159: 677-85.

148. Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. ROCKET AF Steering Committee and Investigators Stroke 2014; 45: 1304-12.

149. Cao L, Pokorney SD, Hayden K, et al. Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke? J Am Heart Assoc 2015; 4: e001573.

150. Horstmann S, Rizos T, Saribas M, et al. Cognitive impairment is not a predictor of failure to adhere to anticoagulation of stroke patients with atrial fibrillation. Cerebrovasc Dis 2015; 39: 325-31.

151. Tavassoli N, Perrin A, Bérard E, et al. Factors associated with under treatment of atrial fibrillation in geriatric outpatients with Alzheimer disease. REAL.FR Group. Am J Cardiovasc Drugs 2013; 13: 425-33.

152. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. ESC Committee for Practice Guidelines (CPG). Eur Heart J 2012; 33: 2719-47.

153. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation 2014; 130: 2071-104.

154. Heidbuchel H, Verhamme P, Alings M, et al.; Advisors: Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; Aug 31.

155. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). ROCKET AF Investigators. JACC 2014; 63: 891-900.

156. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. ROCKET AF Investigators. N Engl J Med 2011; 365: 883-91.

157. Westenbrink BD, Alings M, Connolly SJ, et al. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. J Thromb Haemost 2015; 13: 699-707.

158. Yamada Y, Eto M, Yamamoto H, et al. Gastrointestinal hemorrhage and antithrombotic drug use in geriatric patients. Geriatr Gerontol Int 2012; 12: 751-2.

159. Masclee GM, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014; 147: 784-92.

160. Jia B, Lynn HS, Rong F, Zhang W. Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation. J Cardiovasc Pharmacol 2014; 64: 368-74.

161. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-62.

162. Abraham NS, Castillo DL. Novel anticoagulants: bleeding risk and management strategies. Curr Opin Gastroenterol 2013; 29: 676-83.

163. Holster IL, Hunfeld NG, Kuipers EJ, et al. On the treatment of new oral anticoagulant-associated gastrointestinal hemorrhage. J Gastrointestin Liver Dis 2013; 22: 229-31.

164. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.

165. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open label, randomised, controlled trial. Lancet 2013; 381: 1107-15.

166. Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology Working Group on Thrombosis. JACCardiol 2014; 64: 319-27.

167. Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2011; 32: 1854-64.

168. Flynn R, Doney A. Antithrombotic medicines following intracerebral haemorrhage: where’s the evidence? Ther Adv Drug Saf 2011; 2: 205-11.

169. Andreotti F, Crea F. Defining the role of left atrial appendage closure in atrial fibrillation. Rev Esp Cardiol 2013; 66: 79-82.


Для цитирования:


Ткачева О.Н., Рунихина Н.К., Воробьёва Н.М., Комаров А.Л., Котовская Ю.В., Панченко Е.П., Плохова Е.В., Фролова Е.В., Явелов И.С. АНТИТРОМБОТИЧЕСКАЯ ТЕРАПИЯ В ПОЖИЛОМ И СТАРЧЕСКОМ ВОЗРАСТЕ: СОГЛАСОВАННОЕ МНЕНИЕ ЭКСПЕРТОВ. Кардиоваскулярная терапия и профилактика. 2017;16(3):4-33. https://doi.org/10.15829/1728-8800-2017-3-4-33

For citation:


Tkacheva O.N., Runikhina N.K., Vorobiova N.M., Komarov A.L., Kotovskaya Y.V., Panchenko E.P., Plokhova E.V., Frolova E.V., Yavelov I.S. ANTITHROMBOTIC THERAPY IN ELDERLY AND SENILE AGE: AN EXPERT CONSENSUS. Cardiovascular Therapy and Prevention. 2017;16(3):4-33. (In Russ.) https://doi.org/10.15829/1728-8800-2017-3-4-33

Просмотров: 623


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)